Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population

Fundamental and Clinical Pharmacology

Volumn 21, Issue 4, 2007, Pages 419-426

  Arvanitidis, Kostas ^a   Ragia, Georgia ^a   Iordanidou, Maria ^a   Kyriaki, Sofia ^a   Xanthi, Athanasia ^a   Tavridou, Anna ^a   Manolopoulos, Vangelis G ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

CYP2C19; CYP2C9; CYP2D6; CYP3A5; Genotyping; Greek; Polymorphism

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5;

ADULT; AGED; BLOOD SAMPLING; CONFERENCE PAPER; DNA ISOLATION; ETHNIC GROUP; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GREECE; HUMAN; MALE; NORMAL HUMAN; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; GREECE; HUMANS; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC;

EID: 34447269513     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00510.x     Document Type: Conference Paper

References (49)

1. Meyer U.A. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc. Natl. Acad. Sci. USA (1994) 91 1983 1984.
2. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. (2004) 25 193 200.
3. Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur. J. Clin. Invest. (2003) 33 (Suppl. 2) 17 22.
4. Jain K.K. Applications of AmpliChip CYP450. Mol. Diagn. (2005) 9 119 127.
5. Goetz M.P., Knox S.K., Suman V.J. et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. (2007) 101 113 121.
6. Dahl M.L., Johansson I., Bertilsson L., Ingelman-Sundberg M., Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. (1995) 274 516 520.
7. Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. (1997) 60 284 295.
8. Menoyo A., del Rio E., Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem. Funct. (2006) 24 381 385.
9. Agundez J.A., Ledesma M.C., Ladero J.M., Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. (1995) 57 265 269.
10. Aynacioglu A.S., Sachse C., Bozkurt A. et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. (1999) 66 185 192.
11. Armstrong M., Daly A.K., Blennerhassett R., Ferrier N., Idle J.R. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br. J. Psychiatry (1997) 170 23 26.
12. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369 23 37.
13. Xie H.G., Prasad H.C., Kim R.B., Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. (2002) 54 1257 1270.
14. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. (2001) 52 349 355.
15. Miners J.O., Birkett D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. (1998) 45 525 538.
16. Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. (2002) 72 702 710.
17. Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. (2005) 7 97 104.
18. Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. (2002) 41 913 958.
19. Ward S.A., Helsby N.A., Skjelbo E., Brosen K., Gram L.F., Breckenridge A.M. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br. J. Clin. Pharmacol. (1991) 31 689 692.
20. Goldstein J.A., Ishizaki T., Chiba K. et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics (1997) 7 59 64.
21. Furuta T., Shirai N., Sugimoto M., Nakamura A., Hishida A., Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet. (2005) 20 153 167.
22. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. (2002) 54 1271 1294.
23. Shih P.S., Huang J.D. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos. (2002) 30 1491 1496.
24. Kuehl P., Zhang J., Lin Y. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. (2001) 27 383 391.
25. Roy J.N., Lajoie J., Zijenah L.S. et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug. Metab. Dispos. (2005) 33 884 887.
26. Schur B.C., Bjerke J., Nuwayhid N., Wong S.H. Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR. Clin. Chim. Acta (2001) 308 25 31.
27. Steijns L.S., Van Der Weide J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin. Chem. (1998) 44 914 917.
28. Nasu K., Kubota T., Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics (1997) 7 405 409.
29. van Schaik R.H., van der Heiden I.P., van den Anker J.N., Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem. (2002) 48 1668 1671.
30. Hersberger M., Marti-Jaun J., Rentsch K., Hanseler E. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase. Clin. Chem. (2001) 47 772 774.
31. Tamminga W.J., Wemer J., Oosterhuis B., de Zeeuw R.A., de Leij L.F., Jonkman J.H. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur. J. Clin. Pharmacol. (2001) 57 717 722.
32. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. (2003) 59 303 312.
33. Scordo M.G., Caputi A.P., D'Arrigo C., Fava G., Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res. (2004) 50 195 200.
34. Halling J., Petersen M.S., Damkier P. et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur. J. Clin. Pharmacol. (2005) 61 491 497.
35. Rasmussen J.O., Christensen M., Svendsen J.M., Skausig O., Hansen E.L., Nielsen K.A. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand. J. Clin. Lab. Invest. (2006) 66 129 136.
36. Bozina N., Granic P., Lalic Z., Tramisak I., Lovric M., Stavljenic-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat. Med. J. (2003) 44 425 428.
37. Kimiskidis V.K., Niopas I., Firinidis P.D. et al. Frequency distribution of dextromethorphan O-demethylation in a Greek population. Int. J. Clin. Pharmacol. Ther. (2005) 43 150 153.
38. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. (2005) 5 6 13.
39. Bachmann K.A. Genotyping and phenotyping the cytochrome p-450 enzymes. Am. J. Ther. (2002) 9 309 316.
40. Garcia-Martin E., Martinez C., Ladero J.M., Gamito F.J., Agundez J.A. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur. J. Clin. Pharmacol. (2001) 57 47 49.
41. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics (2002) 12 251 263.
42. Xiao Z.S., Goldstein J.A., Xie H.G. et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. (1997) 281 604 609.
43. Fukushima-Uesaka H., Saito Y., Maekawa K. et al. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab. Pharmacokinet. (2005) 20 300 307.
44. Steimer W., Zopf K., von Amelunxen S. et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. (2004) 50 1623 1633.
45. King B.P., Leathart J.B., Mutch E., Williams F.M., Daly A.K. CYP3A5 phenotype-genotype correlations in a British population. Br. J. Clin. Pharmacol. (2003) 55 625 629.
46. Quaranta S., Chevalier D., Bourgarel-Rey V. et al. Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population. Toxicol. Lett. (2006) 164 177 184.
47. Dai Y., Hebert M.F., Isoherranen N. et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos. (2006) 34 836 847.
48. Kivisto K.T., Niemi M., Schaeffeler E. et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 14 523 525.
49. Kirchheiner J., Brosen K., Dahl M.L. et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand. (2001) 104 173 192.